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ABSTRACT 
 
Background: Isoespintanol is a monoterpene isolated from the leaves of Oxandra xylopioides 
Diels. (Annonaceae) with antioxidant and antiinflammatory effects. It was of interest to know 
whether it has antispasmodic effects such as other known drugs, phloroglucinol and 
trimethoxybenzene, used in therapeutics for treating biliary, urinary and uterine spasms.  
Purpose: to assess whether isoespintanol possesses antispasmodic effects on intestine, uterus 
and bladder.  
Study design: A preclinical study was performed in which isoespintanol, phloroglucinol and 
trimethoxybenzene were evaluated with concentration-contractile response curves (CRC) of 
carbachol in isolated rat intestine and bladder, and with CRC of serotonin (5-HT) in rat uterus. 
Moreover, it was assessed whether isoespintanol interferes with Ca2+ influx by making CRC 
of Ca2+ in high-K+ medium in intestine and bladder.  
Results: isoespintanol non-competitively inhibited the CRC of carbachol with affinity 
constant  (pK) of 4.78 ± 0.09 in intestine and 4.60 ± 0.09 in bladder. Phloroglucinol and 
trimethoxybenzene were also non-competitive antagonists, but isoespintanol was 8 times 
more potent than trimethoxybenzene and similarly potent than phloroglucinol in intestine. In 
bladder, isoespintanol resulted 8 times more potent than trimethoxybenzene. The maximal 
inhibition of contraction followed the order of isoespintanol > trimethoxybenzene > 
phloroglucinol in intestine, and isoespintanol > trimethoxybenzene in bladder. Moreover, 
isoespintanol also completely and non-competitively inhibited the CRC of Ca2+, with a pK of 
5.1 ± 0.1 in intestine, and 4.32 ± 0.07 in bladder. In uterus isoespintanol reduced, completely 
and non-competitively, the contraction produced by 5-HT with pK of 5.05 ± 0.07. 
Conclusions: Results demonstrate that isoespintanol is a very good intestinal, urinary and 
uterine antispasmodic, with higher potency than the other drugs used in therapeutics. The 
mechanism of action of isoespintanol is the interference with Ca2+ influx, at a difference of 
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trimethoxybenzene and phloroglucinol. 
 
Keywords: Isoespintanol; Antispasmodic; Intestine; Detrusor; Uterus; Calcium 
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Abbreviations 
BK: big K+ channels; Cbl: carbachol; CICUAL: Institutional Comitee for Care of Laboratory 
Animals; CONICET: National Council of Scientifical and Technical Research; CRC: 
concentration-contractile response curves; DMSO: dimethylsulphoxide; F: Fisher coefficient 
for variance statistical test; HPLC: high performance liquid chromatography;  5-HT: 
serotonin; I.P.: intraperitoneal; NIH: National Institute of Health; pK: affinity constant; SEM: 
standard error of media.   
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Introduction 
 
 The compound 2-isopropyl-3,6-dimethoxy-5-methylphenol (isoespintanol) is a 
monoterpene isolated from the leaves of Oxandra  xylopioides Diels. (Annonaceae) (Rojano 
et al., 2007a). Annonaceae plants have several therapeutic properties such as antimalaric and 
cytotoxic (Tsabang et al., 2012). It was demonstrated that isoespintanol has antiinflammatory, 
antioxidant and insecticide properties (Rojano et al., 2007a, 2007b, 2008).  
 Here it was evaluated whether isoespintanol had antispasmodic properties in smooth 
muscles. Intestinal and uterine aches are caused by the smooth muscles spasms, while the 
hyperactivity of detrusor becomes in urine loss or bladder incontinence. The usual treatments 
consist in anticholinergics such as hyoscyamine, glycopyrrolate, oxybutinine or scopolamine, 
but they have certain incidence of systemic adverse effects and contraindications in glaucoma 
and prostatic hypertrophy (Brunton et al., 2012). Moreover, two other compounds, 
phloroglucinol (1,3,5-trihydroxybenzene) and its methoxy-derivative 1,3,5-trimethoxy-
benzene are used as oral and intramuscular formulations to treat biliary, urinary and uterine 
spasms, sometimes associated to stones (Boukef et al., 2010). Phloroglucinol has antioxidant 
and spasmolytic activities with weak anticholinergic properties, it reduced the uretheral ache 
triggered by stones and facilitated the expulsion (Dellabella et al., 2005). Trimethoxybenzene 
has a prolonged duration as antispasmodic in comparison to phloroglucinol. It would be 
important to find new compounds with antispasmodic effects without anticholinergic 
properties, in order to avoid the typical adverse effects of those antagonists, such as 
xerostomy, cough associated to the reduction of bronchial secretions, and cardiac palpitations 
among others. 
 The aim of this work was to evaluate whether isoespintanol has antispasmodic effects 
on gastrointestinal, urinary and uterine smooth muscle and the mechanism of action. 
Moreover, its effects were compared with those of the commercially used phlorogucinol and 
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trimethoxybenzene, as positive controls. 
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Materials and methods 
 
 
Animals 
Sprague-Dawley rats (200-280 g) of both sexes were used. Animals were housed and 
allowed to have food and water ad libitum in accordance with the internationally accepted 
principles for the laboratory animal use and care, established by US guidelines (NIH 
publication # 85-23 revised in 1996) and principles in the Declaration of Helsinki, according 
to the Resolution 1047 anexo II-2005, of Consejo Nacional de Investigaciones Científicas y 
Técnicas (CONICET) de la República Argentina. Rats were subjected to a 12 h fasting with 
free access to water before the experiments.    
 
Drugs and solutions 
Isoespintanol (Fig. 1) was previously isolated from the petroleum ether extract of leaves from 
O. xylopioides by Prof. Dr. Benjamín Alberto Rojano from the Universidad Nacional de 
Colombia (headquarter Medellín), who determined the physicochemical properties and 
structure (Rojano et al., 2007a). The purity of this sample was assessed by HPLC analyses, 
for which isoespintanol was dissolved in 10 ml of ethanol (at final concentration of 1 g/l) and 
vortexed for 1 min. Its purity was quantified using a Shimadzu Prominence® modular HPLC 
equipped with a SPD-M20A diode-array detector according to modified method proposed by 
Ultee et al. (2002): isocratic elution with methanol/water (60:40); flow rate of 0.8 ml/min; 
LiChrospher® 100 RP-18 column (5 µm, 250 × 4 mm) (Merck, Darmstadt) thermostated at 
35 °C; injection volume 20 µl. The retention time of isoespintanol was 12.1 min and its purity 
>99% when monitoring at 277 nm (see Supplementary material). 
For the present evaluation, the purified crystalline solid of isoespintanol was dissolved 
in dimethylsulphoxide (DMSO) at concentrations of 0.3, 1, 3 and 10 mM as mother solutions. 
Phloroglucinol (Sigma-Aldrich, St Louis, MO, USA) was dissolved in water at concentrations 
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of 0.1, 0.3, 1, 3, 10 and 30 mM. Trimethoxybenzene (Sigma-Aldrich) was dissolved in 
DMSO at concentrations of 0.1, 0.3, 1, 3, 10 and 30 mM. Verapamil chloride (ICN 
Biomedicals Inc., Horsha, PA, USA) was prepared in concentrations of 0.01, 0.03, 0.1, 0.3 
and 1 mM. Carbamylcholine (carbachol, Sigma-Aldrich), serotonin (5-HT, Sigma-Aldrich) 
and adrenaline (in ampules at 1 g/ml from BIOL, Instituto Biológico Argentino S.A.I.C. 
Buenos Aires, Argentina) were prepared in a series of 1, 2, 7, 20, 70, 200, 700 and 1000 
µg/ml in water. 
In order to reach the desired concentration all drugs solutions were finally diluted in the 
chamber for isolated organs at 1/100. These physiological media were the Tyrode´s solution 
for intestine (composition, in mM, 150 NaCl, 2.7 KCl, 2 MgCl2, 12 NaHCO3, 0.4 PO4H2Na, 
5.5 D-glucose, 1.8 CaCl2 , pH 8.2), Tyrode’s-0Ca by eliminating CaCl2 and Tyrode’s-0Ca-40 
mM K+ by adding 0.6 ml KCl 10% to 20 ml Tyrode’s-0Ca (Ragone et al., 2007), the  
modified Tyrode´s solution with 2.5 mM CaCl2 for bladder strips (Hamada et al., 1997), or 
De Jalon´s solution for uterine tissues (composition, in mM, 9.0 NaCl, 0.5 NaHCO3, 0.5 D-
glucose, 0.4 KCl, 0.1 CaCl2 ) (Livingstone and Livingstone, 1970;  Kitchen, 1984). 
 
Pharmacological studies 
Biological preparations and contractile measurements 
Rats were anesthetized with urethane (1.5 g/kg via I.P.) (Livingstone and Livingstone, 
1970) according to the approved protocol Nr. 015/2015 from the Institutional Commitee for 
the Care of Laboratory Animals (CICUAL) of Facultad de Ciencias Exactas, Universidad 
Nacional de La Plata (UNLP). Then, rats were quickly sacrificed by opening the thorax and 
abdomen. The duodenum and ileum (about 2 cm long) were excised and mounted in 20 ml 
chambers for isolated organs containing Tyrode’s solution at 37 ºC and constantly oxygenated 
with air bubbling, as in previous works (Ragone et al., 2007; Matera et al., 2012; Blanco et 
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al., 2013; Jiménez Hernández et al., 2018). The excised bladder was divided in 3 or 4 
longitudinal slices respectively mounted in chambers with Tyrode´s solution similarly to the 
intestinal portions. Both uterine horns were excised, divided in 4 parts and immersed in De 
Jalon´s solution in chambers at 32 ºC bubbled with air (Kitchen, 1984).  
Each preparation was longitudinally connected to an isometric transducer, either 
FORT100 (World Precision Instruments (WPI), Sarasota, FL, USA) for intestine and bladder, 
or MLT0210/A, (ADInstruments, New South Wales, Australia) for uterine tissues. Tissues 
were equilibrated for at least 45 min at 1 g of pre-load. The signals were simultaneously 
amplified by a 4-channels preamplifier (WPI) and recorded by the Eagle software, or by a 2-
channels Power Lab system (ADInstruments), respectively. 
 
Concentration-contractile response curves with carbachol or serotonin 
Concentration-response curves (CRC) with the agonist carbachol were done in 
intestine and bladder portions by cumulatively adding the solutions to the chamber (obtaining  
final concentrations of 0.01, 0.03, 0.1, 0.3, 1, 3 and 10 g/ml) first in the absence (control) 
and then in the presence of the vehicle or a unique concentration of the antagonist (3, 10, 30 
and 100 µM of isoespintanol; 1, 3, 10, 30, 100 and 300 µM of phloroglucinol; 1, 3, 10, 30, 
100 and 300 µM of trimethoxybenzene; or 0.1, 1 and 10 µM of verapamil). The contractile 
effect of each agonist concentration was expressed as percentage of the maximal contraction 
of tissue obtained with the second control-CRC (% Emax, percentage of maximal effect). The 
antagonist concentrations were assessed by individually adding them 5 min before the 
respective CRC, in growing order.  
In uterine tissue the baseline had spontaneous and large phasic contractions, and the 
consecutive CRC of the agonist 5-HT were done by reaching cumulative final concentrations 
of 0.01, 0.03, 0.1, 0.3, 1 and 3 µg/ml. The effect of each 5-HT concentration was measured as 
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the maximal amplitude of the phasic contractions and expressed as percentage of the maximal 
contraction in the control CRC (that obtained in the absence of antagonist). 
 
Concentration-contractile response curves with CaCl2 
After stabilization of intestines, consecutives CRC of Ca2+ were done in the 
depolarizing media of Tyrode-0Ca-40 mM K+. Each CRC was obtained in the chambers of 20 
ml by cumulatively adding CaCl2 (0.2 ml of the solutions with 0.882, 1.764, 5.3, 18.5, 53 and 
185 mg/ml) to reach concentrations of 0.079, 0.238, 0.636, 2.14, 6.44 and 21.44 mM, first in 
the absence (control) and then in the presence of unique, consecutive and growing 
concentrations of the antagonists. The contractile effect of each Ca2+ concentration was 
expressed as percentage of the maximal contraction of tissue obtained in the second control of 
Ca2+-CRC (as % Emax). Each antagonist was added 5 min before the depolarization with 
high-K+ in Tyrode’s-0Ca and remained throughout the Ca2+-CRC.  
 
Concentration-relaxing response curves of adrenaline and isoespintanol in uterus 
 After contracting uterine tissue with 2 µg/ml 5-HT, relaxation was obtained by 
cumulative addition of adrenaline to obtain steps of final concentrations of 0.01, 0.03, 0.1, 
0.3, 1, 3 and 10 µg/ml. Similarly, relaxation was obtained by cumulatively adding 
isoespintanol to obtain steps of final concentrations of 3, 13, 43 and 143 µM, and as a 
negative control it was added the vehicle (DMSO) in steps. 
 
Pharmacological parameters calculation 
From the CRC, the concentration to 50% of maximal effect of the agonist (pEC50 = –
log EC50, expressed in M) and the affinity constant (pKB´) of the non-competitive antagonists 
(isoespintanol, phloroglucinol, trimethoxybenzene and verapamil) were calculated. This 
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parameter represents the affinity of the non-competitive metactoid antagonist for its cellular 
site of interaction (van Rossum, 1963; Kenakin, 2014). The pKB´ was calculated using the 
following equation:  -log KB´ = –log [B’] + log [(EA – EAB’max)/(EA – EAB’) -1], where [B’] is 
the concentration of the non-competitive antagonist (in M), and EA, EAB’ and EAB’max are the 
maximal effects of the agonist respectively in the absence (A) and in the presence of the 
antagonist (AB’) and under its maximal concentration (AB’max), considering complete 
blockade with EAB’max as zero. The pEC50 and pKB´ were calculated from each individual 
series of CRC done in a tissue, and then the mean ± SEM was calculated. 
Moreover, the values of pD´2 were calculated by using the Gaddum method (Kenakin, 
2014). This method compares two concentrations with the same effect of the agonist 
(carbachol) in the absence ([A]) and the presence of the antagonist ([A]B´). Then, it is possible 
to obtain the linear regression between  the several paired values of  1/[A]B´ versus 1/[A] and 
calculate the Gaddum equation as: KB´ = [B’]/(slope – 1), where ]´[B  is the antagonist 
concentration  (in M), and its affinity is pKB´= -log KB´. Fig. 3 shows the calculation of 
isoespintanol affinity (as pK) from the CRC obtained in intestine (Fig. 2a).  
Also, the IC50 (in µM) was calculated by interpolation on the curve E vs [B´] built  
from the effects of a CRC series done in each individual tissue, at a constant agonist 
concentration, generally which triggers the maximal effect, as previously described (Blanco et 
al., 2013). A comparison among IC50 of drugs was done in order to estimate differences in 
potency, which is defined as the ratio between the concentrations needed to reach the same 
effect.  
 
Statistical methods 
All results are expressed as means ± SEM (standard error of media). The statistical 
comparison was done by two-way ANOVA test for multiple comparisons, where the variables 
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were: treatment and –log [agonist]. The ANOVA results were expressed by F (Fisher 
coefficient for variance statistical test) and its significance (p). After the ANOVA, the 
Bonferroni´s a posteriori test for comparison with the respective point of the control CRC 
was done. The statistical analyses were done with Graph Pad Prism 4.0 software. The one-
way ANOVA for comparing more than two values, and the Student’s t-tests were also used 
when necessary. In all tests, p values < 0.05 were considered significant. 
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Results 
Antispasmodic effects on intestinal muscles 
 Isoespintanol was a non-competitive antagonist of the CRC of carbachol (pEC50 = 
5.84 ± 0.06) since it reduced the maximal effects dependently on its concentration (Fig. 2a). 
Table 1 shows the values of isoespintanol affinity calculated as pD´2 by two methods, 
traditional and Gaddum´s (showed in Fig. 3). As it was expected, the affinity constant was 
independent on the method, the agonist or the antagonist concentration. The pD´2 =  pK was 
4.78 ± 0.09, while the IC50 of isoespintanol resulted 12.5 ± 4.2 µM (n = 8). Similar behavior 
showed the other known antispasmodics phloroglucinol (pD´2 = pK = 4.77 ± 0.12, IC50 = 7.1 
± 1.31 µM, n = 4) and trimethoxybenzene (pD´2 = pK = 4.39 ± 0.09, IC50 = 152 ± 33 µM, n = 
5) (Fig. 2b and 2c). Fig. 2d compares the inhibition curves obtained from the CRC shown in 
a, b and c for isoespintanol, phloroglucinol and trimethoxybenzene and their IC50. It can be 
concluded that isoespintanol showed similar potency than phloroglucinol and both of them 
were more potent than trimethoxybenzene.  
 
Antispasmodic effects on bladder 
Isoespintanol also was a non-competitive antagonist of the CRC of carbachol (pEC50 = 
5.70 ± 0.11, n = 5) on bladder trips (Fig. 4a). The affinity of isoespintanol was calculated as 
pD´2 = pK = 4.60 ± 0.09 (see Table 1), while the IC50 of isoespintanol resulted 38.64 ± 3.1 
µM. Similar behavior showed trimethoxybenzene (pD´2 = pK = 4.01 ± 0.12), although it did 
not inhibit the contraction up to 50%, by which it was calculated the IC40 = 231 ± 36 µM (n = 
4) (Fig. 4b). In contrast, phloroglucinol did not inhibit the CRC of carbachol (Fig. 4c, n = 6). 
Considering that the non-competitive inhibition of isoespintanol could be due to inhibition of 
Ca2+ influx to the smooth muscle of bladder, we compared these results with the effect of the 
known Ca2+ channels blocker verapamil, as a positive control. Verapamil also non-
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competitively inhibited the CRC of carbachol (Fig. 4d), with an IC50 of 0.83 ± 0.05 µM (n = 
4), and pD´2= pK= 5.80 ± 0.13 or pK = 6.06  0.05, according to the method (Table 1). Fig. 5a 
shows that isoespintanol was about 40 times less potent than verapamil but about 6 times more 
potent than trimethoxybenzene. 
Moreover, isoespintanol was assessed in the tonic contracture of bladder strips 
developed by 0.7 µg/ml carbachol, to which relaxed up to about 66% of the initial tone with a 
IC50 of 11.5 ± 0.5 µM (n = 4) (Fig. 5b), after substracting the relaxation due to the vehicle, 
DMSO (less than 24% of tonic contraction). Also, isoespintanol reduced the phasic 
contractions induced by electrical field stimulation, with a IC50 of 35.1 ± 20 µM (n = 4) to 
reach a maximal inhibition of about 44% of the phasic contraction. 
 
Antispasmodic effects on uterus 
 Isoespintanol was a non-competitive inhibitor of the 5-HT CRC (pEC50= 6.71 ± 0.07, n = 
6) in uterus (Fig. 6a). The affinity of isoespintanol was calculated as pD´2 = pK = 5.05 ±  0.06 
(see Table 1), while the IC50 of isoespintanol resulted 13.7 ± 2.7 µM. Moreover, isoespintanol 
relaxed the tonic contracture of uterus developed by 1 µg/ml 5-HT. After substracting the 
relaxation due to the vehicle DMSO, isoespintanol relaxed uterus in about 55% of the tonic 
contracture, with a IC50 of 7.10 ± 1.16 µM (Fig. 6 b-d). Isoespintanol was less potent than 
adrenaline, which relaxed completely (96 ± 2%) the tonic contracture of 5-HT, with a IC50 of 
1.00 ± 0.31 µM (Fig. 6d). 
 
Antispasmodic mechanisms on smooth muscle 
In order to evaluate whether the antispasmodic non-competitive effect of isoespintanol 
was due to inhibition of calcium influx to the smooth muscle, its effects on CRC of Ca2+ were 
assessed in intestinal and bladder muscles under high [K+] depolarization (Tyrode-0 Ca-40 
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mM K+). In both smooth muscles isoespintanol was a non-competitive antagonist of Ca2+ 
influx (Fig. 7a and b). In intestinal muscle the Ca2+-CRC showed a pEC50 of 2.67 ± 0.04 (n = 
11) while the affinity constant of isoespintanol resulted pD´2 = pK = 5.10 ± 0.1 (n = 11) and 
pK = 4.65 ± 0.15 by the Gaddum method (Table 1). The IC50 of isoespintanol was 35.6 ± 15.9 
µM. In bladder muscles, the Ca2+-CRC exhibited a pEC50 of 2.77 ± 0.09 (n = 4), while the 
non-competitive affinity constant of isoespintanol was calculated as pD´2 = pK = 4.32 ± 0.07 
µM (n = 11) (Table 1). The IC50 of isoespintanol was 98.6 ± 11.86 µM. Contrarily, 
trimethoxybenzene did not inhibit the Ca2+-CRC proportionally to its concentration (Fig. 7c), 
by which it is not considered antagonist of Ca2+  influx. Table 1 also shows that the pK of 
verapamil was higher of the isoespintanol pK in both intestine and bladder with the agonists 
and Ca2+ CRC´s. 
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Discussion 
 This work demonstrates that isoespintanol has antispasmodic effects on intestinal, 
bladder and uterine smooth muscles, with higher potency than trimethoxybenzene, which is 
used in oral or intramuscular formulations to treat biliary, urinary, intestinal and uterine 
spasms consequent to stones (Boukef et al., 2010). So, isoespintanol appears as a promisory 
therapeutic agent similarly potent to phloroglucinol against intestinal spasms, more potent 
than trimethoxybenzene in bladder, and also antispasmodic in uterus. 
Our results obtained in isolated organs of rat showed that isoespintanol has better 
properties than classic antiespasmodics as hyoscine, used for intestinal and uterine spasms, 
since it was not antimuscarinic but a non-competitive antagonist, as well as 
trimethoxybenzene and phloroglucinol. Because of that, isoespintanol offers an advantage 
over anticholinergic drugs that is to lack the adverse effects such as xerostomy and 
palpitations. Comparing the other drugs used for treating urinary spasms, it was reported that 
the methoxy substituents of trimethoxybenzene extend the effect of phloroglucinol and 
increase the potency (Dellabella et al., 2005; Goswami et al., 2016; Zhuang et al., 2003). 
Nevertheless, we did not find antispasmodic effects of phloroglucinol in bladder, while other 
report described very weak inhibition of phloroglucinol on normal intestinal peristalsis under 
spasms (Cahen, 1962). More recently, a meta-analysis of clinical reports concluded that only 
one randomized clinical trial found that phloroglucinol was superior to placebo treating 
abdominal pain, and that there is insufficient data to justify the wide-spread prescription of  
phloroglucinol (Blanchard et al., 2018). Moreover, there are medicines with anticholinergic 
and calcium antagonist properties to synergistically reduce the anormal contractions of 
bladder due to inestability or hiperactivity of detrusor (Sugaya et al. 2012). To this therapeutic 
group belong oxybutinine and propiverine, which have strong anticholinergic activity but 
weak effect as calcium channels blocker (Hamada et al., 1997; Sakakibara et al. 2016). Other 
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antimuscarinic drugs such as tolterodine and imidafenacin are effective because also reduce 
the bladder epithelial cells ATP release, which contributes to contractile hyperactivity 
(Nishijima et al. 2009). In comparison to all these drugs, isoespintanol has good 
antispasmodic properties, and it was a non-competitive antagonist in the three types of smooth  
muscle, independently on the receptor that triggers the contraction (M3 in the intestine and 
detrusor, and 5-HT2 in uterus) and on the tissue differential characteristics (total receptors 
number and efficiency of stimulus-response coupling) (Kenakin, 2014). The affinity constant 
(pK or pD´2) of isoespintanol estimated in uterine tissue was not significantly different to that 
obtained in intestine and in bladder (Table 1). Also, a good correspondence was found 
between classic method of pD´2 based in Ariens theory (Van Rossum, 1963) and pK´B 
obtained by using the Gaddum method (Kenakin, 2014) as showed in Table 1. These results 
suggested that isoespintanol had the same binding site and mechanism on the three types of 
smooth muscle, so we assessed whether it was the L-type Ca2+ channels. 
The most important cellular event for triggering contraction in all smooth muscles is 
the Ca2+ influx trough the voltage-dependent L-type channels. Our results showed that 
isoespintanol was also a non-competitive antagonist in the CRC of Ca2+ on intestine and 
bladder, while trimethoxybenzene did not interfere with Ca2+ influx. So, the potency of 
isoespintanol to interfere with Ca2+ influx was compared with verapamil, a known frequency-
dependent Ca2+-channels blocker. Here we showed that verapamil also was a non-competitive 
antagonist of the carbachol-CRC in bladder, as previously we have shown in intestinal smooth 
muscle on the carbachol and Ca2+ CRC´s (Blanco et al., 2013). This behavior is due to the 
binding of verapamil inside of the channel, which is different to the dihydropyridines calcium 
blockade, since they bind to the external Ca2+ site and compete with this ion (Spedding, 
1985). Verapamil showed higher affinity than isoespintanol, since its pD´2 (or pK) was about 
6 in both Ca2+ and acethylcholine CRC´s on intestinal muscle (Blanco et al. 2013), as well as 
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in carbachol CRC on bladder (Fig. 4d). All these values agree with previous reports that 
estimated an affinity of about 1 µM for verapamil (Ishii et al., 1985). Isoespintanol was 9 
times less potent than verapamil in intestine and 40 times less in bladder (comparing the IC50). 
There are differences in the IC50 of isoespintanol in bladder estimated from the inhibition of 
the tonic contracture induced by carbachol (about 11 µM) and that estimated from the phasic 
contractions induced by electrical stimulation or by the CRC of carbachol (about 35-40 µM). 
It is known that tonic contracture of smooth muscles are completely dependent on Ca2+ 
channels opening, while phasic contraction could have other contributions in some smooth 
muscles (Zhao et al. 1993). In the phasic spikes of bladder occurs the activation followed by 
inactivation of K+ channels (mostly BK), which mantain the resting potential with alternancy 
between activation and repolarization of L-type Ca2+ channels, generating the spontaneous 
automaticity (Petkov, 2011; De la Fuente et al., 2014; Philyppov et al., 2016). The effect of 
isoespintanol could also be due to direct activation of K+ channels. Nevertheless, the fact that 
isoespintanol was also a non-competitive antagonist on the Ca2+-CRC allows to reject this 
hypothesis, because in a high-K+ medium the K+-channels openers are inactive as relaxants 
(Quast, 1993). So, the differences in the isoespintanol sensitivity in bladder could be due to 
differences in either, the number of Ca2+ channels involved in tonic and phasic contractions or 
their activation threshold. Moreover, the higher antispasmodic potency of isoespintanol than 
that of phloroglucinol and trimethoxybenzene especially in bladder, may be dependent on the 
fact that only isoespintanol was a Ca2+-non-competitive antagonist.  
The uterine muscle has also spontaneous activity with contractile spikes of great 
amplitude, in which K+ channels play an important role to activate Ca2+ channels (Smith et al. 
2007). Isoespintanol relaxed the tonic contraction induced by 5-HT and non-competitively 
inhibited the CRC of 5-HT in uterus. However, isoespintanol relaxed the tonic contraction (up 
to 45%) less than adrenaline (up to 96% of contraction) and it was 7 times less potent than the 
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β-adrenergic agonist. These differences agree with the different mechanisms of action of 
adrenaline (activation of PKA by the β2-receptor with affinity estimated in about 0.01 µM) 
and isoespintanol (interference with Ca2+ influx with affinity estimated in about 10 µM). 
 
Conclusions 
Isoespintanol demonstrated to be a good antispasmodic in rat intestine, bladder and uterus, 
which non-competitively antagonized the CRC of carbachol and serotonin with similar pK 
(about 5) and IC50 between 7 and 38 µM. It also non-competitively interfered with the Ca2+ 
influx to smooth muscle as well as verapamil does, although isoespintanol was less potent 
than this drug. So, isoespintanol appears as a promisory therapeutic agent in comparison to 
other therapeutic drugs. Isoespintanol was similarly potent to phloroglucinol against intestinal 
spasms, while both of them were 8 times more potent than trimethoxybenzene. In bladder, 
isoespintanol was 40 times less potent than verapamil but also about 6 times more potent than 
trimethoxybenzene, while phloroglucinol did not exhibit antispasmodic effect against 
carbachol. Moreover, isoespintanol reduced the phasic and tonic serotonin-dependent 
contractions in uterus, although it was about 50% less relaxant and 7 times less potent than 
adrenaline. Although more studies must be done in human tissues, it is important to note that 
generally the less potent drugs are used in therapeutics, in order to gain selectivity among the 
different tissues and to reduce adverse effects. So, isoespintanol represents a new 
pharmacological tool with good perspectives for the treatment of intestinal and uterine spasms 
as well as in the hyperactivity of detrusor. 
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Legend to the Figures: 
 
Fig. 1: Chemical structures of isoespintanol (a), phloroglucinol (b) and trimethoxybencene 
(c). 
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Fig. 2: Effects on rat isolated intestines: Concentration-contractile response curve (CRC) of 
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carbachol in the absence and the presence of several concentrations (in µM) of isoespintanol 
(a), phloroglucinol (b), and trimethoxybencene (c). The respective curves of inhibition are 
showed in (d) for comparing the IC50. Two way ANOVA: by treatment: F was 90.4,  82.68 
and 81.28 respectively for a, b and c (all p < 0.0001); by log carbachol: F was 167.0, 339.5 
and 397.3 respectively for a, b and c (all p < 0.0001). 
 
 
Fig. 3: Calculation of the affinity constant of  the non-competitive antagonist isoespintanol on 
its own receptor by using the Gaddum method (data from the CRC shown in Fig. 2a). pK = 
4.84 ± 0.15. See description in section Methods ([A]: carbachol concentration, [A]-B’: 
carbachol concentration in the presence of isoespintanol). 
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Fig. 4: Effects on rat isolated bladder strips: Concentration-contractile response curve (CRC) 
of carbachol in the absence and the presence of several concentrations (in µM) of 
isoespintanol (a), trimethoxybencene (b), phloroglucinol (c) and verapamil (d). Results are 
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showed as media ± SEM. Two-way ANOVA: by treatment: F was 95.39,  28.01, and 589 
respectively for a, b and d (all p < 0.0001) and 1.6 for c (p > 0.05); by log carbachol: F was 
271.5, 964.7, 1138 and 896.7 respectively for a, b, c and d (all p < 0.0001). 
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Fig. 5: Effects on bladder strips: Comparison of the inhibition curves of isoespintanol, 
trimethoxybenzene, and verapamil in the CRC of carbachol shown in Fig. 4 (a), of 
isoespintanol in the tonic contracture developed by carbachol after substracting the effect of 
vehicle DMSO (b), and isoespintanol on the phasic contractions induced by electrical field 
stimulation (c). The IC50 of isoespintanol were 38.64 ± 3.1, 11.5 ± 0.5, and 35.1 ± 20 µM 
respectively for a (n = 5), b (n = 4) and c (n = 4). 
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Fig. 6: Effects on rat isolated uterus: (a) Concentration-contractile response curves (CRC) of 
serotonin (5-HT) in the absence and the presence of several concentrations of isoespintanol 
(in µM)  (two-way ANOVA: by treatment: F was 92.4 (p < 0.0001); by log [carbachol]: F was 
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50.71 (p < 0.0001). (b) Typical recordings of uterus contractions before and after adding 1 
µg/ml 5-HT and subsequent addition of either DMSO (upper) or growing concentrations of 
isoespintanol (lower). (c) Inhibition curves of DMSO and isoespintanol + DMSO; (d) 
Comparison between inhibition curves of adrenaline and isoespintanol (after substracting the 
DMSO effect).  
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Fig. 7: Effects on calcium: Concentration-contractile response curve of Ca2+ in Tyrode-0 
Ca2+-40 mM K+ media, in the absence and the presence of several concentrations of 
isoespintanol in rat intestines (a) and bladder (b), and in the presence of trimethoxybencene in 
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bladder (c). The antagonists concentration are expressed in µM. Two-way ANOVA: by 
treatment: F was 89.14,  51.5 respectively for a and b (both p < 0.0001) and 2.46 for c (p < 
0.05); by log [carbachol]: F was 182.5, 280 and 176.3 respectively for a, b and c (all p < 
0.0001).  
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Table 1. Comparison of the affinity constants obtained by the traditional method (pD´2) and 
by the Gaddum method with linear regression (pK) for the non-competitive antagonists 
isoespintanol (ISO) and verapamil in the protocols assessed by means of CRC in different 
tissues and agonists.  
 
Tissue Antagonist 
[Antagonist] 
(µM) Agonist 
pK by Gaddum 
method 
pD´2 
 traditional 
method 
Intestine 
isoespintanol 
10 Cbl 4.84 ± 0.15 (n = 4) 4.78 ± 0.09 (n = 29) 
10 Ca+2 4.65 ± 0.15 (n = 5) 5.10 ± 0.10 (n = 36) 
Verapamila 
0.1 Cbl 6.17± 0.16 (n = 4) a 6.22 ± 0.15 (n = 19) 
0.1 Ca+2 6.64± 0.28 (n = 4) a 6.50 ± 0.11 (n = 10) 
Bladder 
isoespintanol 
30 Cbl 4.54 ± 0.04 (n = 4) 4.60 ± 0.09 (n = 20) 
100 Ca+2 4.23 ± 0.06 (n = 4) 4.32 ± 0.07 (n = 29) 
Verapamil 1 Cbl 6.06 ± 0.05 (n = 4) 5.80 ± 0.13 (n = 9) 
Uterus  isoespintanol 10 5-HT 5.40 ± 0.20 (n = 5) 5.05 ± 0.06 (n = 5) 
 
See description of the methods in the respective section. Cbl: carbachol, 5-HT: serotonin 
a From Blanco et al., 2013. 
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